Qiu Mantang, Yang Xin, Hu Jingwen, Ding Xiangxiang, Jiang Feng, Yin Rong, Xu Lin
Department of Thoracic Surgery, Nanjing Medical University Affiliated Cancer Institute of Jiangsu Province, Nanjing, China.
PLoS One. 2013 Aug 19;8(8):e72251. doi: 10.1371/journal.pone.0072251. eCollection 2013.
The correlation between xeroderma pigmentosum group D (XPD) polymorphisms (Lys751Gln and Asp312Asn) and clinical outcomes of non-small cell lung cancer (NSCLC) patients, who received platinum-based chemotherapy (Pt-chemotherapy), is still inconclusive. This meta-analysis was aimed to systematically review published evidence and ascertain the exact role of XPD polymorphisms.
Databases of MEDLINE and EMBASE were searched up to April 2013 to identify eligible studies. A rigorous quality assessment of eligible studies was conducted according the Newcastle-Ottawa Quality Assessment Scales. The relationship between XPD polymorphisms and response to Pt-chemotherapy and survival was analyzed.
A total of 22 eligible studies were included and analyzed in this meta-analysis. The overall analysis suggested that the XPD Lys751Gln polymorphism was not associated with response to Pt-chemotherapy or survival. However, the XPD 312Asn allele was significantly associated with poor response to Pt-chemotherapy compared with the Asp312 allele (Asn vs. Asp: OR = 0.435, 95% CI: 0.261-0.726). Additionally, the variant genotype of XPD Asp312Asn polymorphism was associated with favorable survival in Caucasian (AspAsn vs. AspAsp: HR = 0.781, 95% CI: 0.619-0.986) but unfavorable survival in Asian (AspAsn+AsnAsn vs. AspAsp: HR = 1.550, 95% CI: 1.038-2.315).
These results suggest that XPD Asp312Asn polymorphism may function as a predictive biomarker on platinum-based chemotherapy in NSCLC and further studies are warranted.
着色性干皮病D组（XPD）基因多态性（Lys751Gln和Asp312Asn）与接受铂类化疗的非小细胞肺癌（NSCLC）患者临床结局之间的相关性仍无定论。本荟萃分析旨在系统评价已发表的证据，并确定XPD基因多态性的确切作用。
检索截至2013年4月的MEDLINE和EMBASE数据库，以识别符合条件的研究。根据纽卡斯尔-渥太华质量评估量表对符合条件的研究进行严格的质量评估。分析XPD基因多态性与铂类化疗反应及生存之间的关系。
本荟萃分析共纳入并分析了22项符合条件的研究。总体分析表明，XPD Lys751Gln基因多态性与铂类化疗反应或生存无关。然而，与Asp312等位基因相比，XPD 312Asn等位基因与铂类化疗反应差显著相关（Asn与Asp：OR = 0.435，95% CI：0.261 - 0.726）。此外，XPD Asp312Asn基因多态性的变异基因型在白种人中与较好的生存相关（AspAsn与AspAsp：HR = 0.781，95% CI：0.619 - 0.986），但在亚洲人中与较差的生存相关（AspAsn + AsnAsn与AspAsp：HR = 1.550，95% CI：1.038 - 2.315）。
这些结果表明，XPD Asp312Asn基因多态性可能作为NSCLC患者铂类化疗的预测生物标志物，值得进一步研究。
